With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results